Aromatherapy Treatment Plan & Home Program

Date/Time: [Date and time of documentation]

Setting: [clinic / inpatient / home visit]

Visit Type: [initial / follow-up]

Patient Name: [Full name]

MRN: [Medical record number]

DOB: [MM/DD/YYYY]

Author/Credentials: [Name, credentials]

Reason for Note: Aromatherapy treatment planning and home program instruction for [symptom/goal]

Consent Status: [Informed consent obtained for complementary therapy and in-session application / Refused / Deferred] (If consent not obtained, document reason and do not proceed to home program.)

Clinical Context & Indication

[Presenting symptom(s) prompting aromatherapy and clinical diagnosis or symptom-based indication]

• Baseline severity/impact: [Numeric 0–10 scale / frequency count / sleep latency / patient-centered impact statement / Baseline not obtained]
• Therapeutic intent: Adjunctive use alongside standard care for [target symptom/goal]

Patient Factors & Preferences

• Scent preferences: [Preferred aromas / Not assessed]
• Scent aversions/triggers: [Aversions or odor-triggered symptoms / None / Not assessed]
• Prior essential oil use: [Routes used, diluted vs. undiluted, outcomes, adverse reactions / None / Not assessed]
• Cultural/spiritual considerations: [Relevant beliefs or practices / None / Not assessed]
• Household context: [Children in home / pregnancy in household / pets / shared spaces / ventilation constraints / Not assessed]

Safety Screening

(Use explicit determinations. Document "Not assessed" for unknowns rather than leaving blank.)

• Allergy/contact dermatitis history: [Cleared / Not cleared – reason / Not assessed] (fragrance allergy, atopy, prior reactions)
• Skin status: [Cleared / Not cleared – reason / Not assessed / Not applicable – topical not planned] (wounds, active dermatitis, impaired barrier)
• Respiratory sensitivity: [Cleared / Not cleared – reason / Not assessed] (asthma, COPD, odor-triggered migraine)
• Neurologic risk: [Cleared / Not cleared – reason / Not assessed] (seizure disorders)
• Pregnancy/lactation status: [Cleared / Not cleared – reason / Not assessed / Not applicable]
• Medication/comorbidity risk flags: [None identified / Anticoagulants / hepatic disease / renal disease / endocrine-sensitive conditions / Not assessed]
• Age category: [Pediatric – adjusted concentration required / Adult – standard / Geriatric – adjusted concentration required]
• Pet exposure: [Cleared / Not cleared – reason / Not assessed / Not applicable – diffusion not planned]
• Internal use: [Not part of plan / Not recommended]

Final safety determination: [Cleared for topical / Cleared for inhalation / Cleared for diffusion] (select all that apply) / [Not cleared – reason]

(If not cleared, document "Aromatherapy home program not recommended" and alternatives discussed. Do not proceed to subsequent sections.)

Goals

(List 1–3 problem-oriented goals in SMART format.)

• [Symptom/Problem]: baseline [value] → target [value] within [timeframe]; [functional outcome]
• [Education/safety goal if applicable]: Patient [demonstrates safe use / verbalizes stop criteria] by end of visit

Selected Modalities

(Include only modalities recommended. Group by problem if addressing multiple symptoms.)

[Problem/Symptom Targeted]

• Modality: [Inhalation via personal inhaler / aroma strip / room diffusion / topical application / compress / bath/shower aromatherapy]
• Indication & rationale: [Link to symptom and patient preference]
• Route/application site: [Specify site or device]
• Frequency & duration: [Sessions per day, duration per session, or applications per day for number of days]
• Maximum exposure cap: [Daily or weekly limit]
• Environmental constraints: [Ventilation requirements, shared space considerations]

(Repeat modality block for each additional modality recommended.)

Blend Specification

(Create separate entry for each blend. Do not assume interchangeability between routes.)

• Blend name/identifier: [Name or ID]
• Intended route(s): [Topical / Inhalation / Diffusion]
• Ingredients:
  • [Common name] ([Botanical name]) – [volume in mL or drops]
• Carrier/base: [Type and total volume] (for topical blends)
• Final concentration: [X]% ([standard adult / sensitive skin / pediatric / geriatric] dilution)
• Recipe notes: Total batch size [X] mL; drop conversion assumption: [20 drops ≈ 1 mL or as specified]
• Safety constraints: [Phototoxicity warnings / dermal maximums / age restrictions / None]
• Product verification: [Verified – source/brand / Unverified patient-supplied oils – safety-only education provided without specific blend endorsement]

(Repeat blend block for each additional blend.)

Dosing & Dilution Instructions

(Provide route-specific dosing with explicit maximums. If product verification incomplete, document "Dosing not provided due to incomplete product verification.")

• Topical: [Amount per application], [site(s)], maximum [X] applications per day, maximum area [specify]
• Inhalation: [Duration per session], maximum [X] sessions per day, minimum [X] minutes between sessions
• Diffusion: [On/off cycle], maximum [X] minutes total per day, [room size or ventilation guidance]
• Maximum daily exposure cap: [Define limits across all routes if using multiple]
• Trial period before reassessment: [Timeframe, e.g., 1–2 weeks]

Safety Precautions & Stop Criteria

• Expected minor effects: [Mild transient headache, mild skin warmth, or other expected effects / None anticipated] (Clarify acceptable vs. concerning threshold.)
• Immediate stop criteria: Skin reactions (burning, blistering, rash, hives, swelling); respiratory symptoms (cough, wheeze, chest tightness, shortness of breath); neurologic/systemic symptoms (dizziness, fainting, severe headache, confusion, vomiting); eye or mucosa exposure
• First steps if reaction occurs: Stop exposure immediately; for topical, wipe off with carrier oil then wash with soap and water; remove from exposure area; ventilate room
• Escalation guidance: [When to contact clinic / when to seek urgent care / when to call emergency services]
• Poison Control (U.S.): 1-800-222-1222 or poisonhelp.org (for accidental ingestion or significant exposure)
• Patient understanding confirmed: [Red flags reviewed; patient verbalized understanding of stop criteria and actions / Needs reinforcement – plan documented]

Patient Education & Teach-Back

• Topics covered: [Dilution principles / route restrictions / phototoxicity avoidance / child safety / pet safety / diffusion ventilation / storage and labeling / avoiding mucosa and eyes]
• Teach-back result: [Patient can state when and how to use, maximum frequency, stop criteria, and actions for adverse exposure / Needs reinforcement – plan documented]
• Materials provided: [Written handout / label instructions / dosing chart / None]
• Barriers & accommodations: [Vision / dexterity / language / cognitive impairment / caregiver involvement / None identified]

Follow-Up Plan

• Follow-up interval: [Date or timeframe / No follow-up planned – rationale and re-contact instructions provided]
• To be reassessed: [Symptom scores, adverse effects, adherence, PRN medication use, functional impact]
• Decision criteria: Continue unchanged if goals met and tolerated; adjust dilution or modalities if partial response; discontinue if adverse effects or no benefit; refer/escalate as indicated (dermatology for dermatitis, medical evaluation for respiratory symptoms)

Care Coordination

(Include only when relevant to complex care or specific clinical concerns.)

• Communications: [Primary clinician or treating team notified of aromatherapy plan, contraindications identified, or recommendations shared]
• Referrals: [Specialty referrals placed or recommended]
• Relevant clinical context: [Considerations related to cancer care, respiratory disease, anticoagulation, pregnancy, or complex comorbidity]

Author Signature/Credentials: [Electronic signature and credentials]

Date/Time: [Date and time of signature]